This trial is active, not recruiting.

Condition atherosclerosis
Sponsor Piedmont Healthcare
Collaborator Abbott
Start date October 2011
End date July 2017
Trial size 170 participants
Trial identifier NCT00969865, iCARE


This study will evaluate the effectiveness of an individualized approach to diagnosing and/or treating atherosclerosis. This will be done by combining genetic information, lifestyle information, participant education, and imaging tests to track diagnoses, therapies, and treatment on two groups: 1) Standard Management Group (diagnosed and/or treated according to standard of care) and 2) Individualized Management Group (standard of care plus genetic testing and coronary artery calcium scans).

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Observational model case control
Time perspective prospective
Participants receiving, in addition to standard of care, blood tests for markers of heart disease, DNA and RNA analysis, and coronary artery calcium scan.
Participants who receive standard of care.

Primary Outcomes

To determine the proportion of subjects and patients who are diagnosed with subclinical and clinically significant coronary atherosclerosis with the PHI-ACE-iCARE approach, compared to the current guideline-driven approach.
time frame: 6 months, 12 months, 18 months

Secondary Outcomes

To determine the proportion of patients who receive appropriate revascularization procedures for clinically significant coronary atherosclerosis with the PHI-ACE-iCARE approach, compared to the current guideline-driven approach.
time frame: 6 month, 12 months, 18 months

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - No known coronary artery disease - no prior coronary disease by cardiac catheterization (≤39% in any major epicardial vessel) - no prior myocardial infarction - no prior ST-elevation myocardial infarction (1 mm ST-elevation in 2 contiguous leads) - no prior non-ST-elevation myocardial infarction (CK-MB > 2x ULN or elevated troponin that is indicative of myocardial necrosis based on local institutional cutpoints) - no prior coronary revascularization procedure - Intermediate or high Framingham Risk Score (10-year risk 10% or greater) - Ability and willingness to provide consent and Authorization for use of PHI Exclusion Criteria: - Presence of known cardiomyopathy - Presence of permanent pacemaker, defibrillator, or CRT device - Presence of clinically significant, uncontrolled arrhythmia (chronic or paroxysmal atrial fibrillation is NOT an exclusion. Arrhythmias treated successfully with ablation are not an exclusion. - Presence of a known genetic abnormality of cholesterol metabolism (e.g. familial hypercholesterolemia) - Inability or unwillingness to adhere to follow up schedule - Inability or unwillingness to provide informed consent and Authorization for use of PHI

Additional Information

Official title Individualized Comprehensive Atherosclerosis Risk-reduction Evaluation Program
Principal investigator Joseph Miller, MD
Description The purpose of this proposal is to create a large, community-based demonstration project to evaluate the value of a highly individualized approach to atherosclerosis risk reduction. In this project we set out to compare the delivery of appropriate therapies and resource utilization using current national guidelines for the management of atherosclerosis and will compare this to using a highly individualized approach for atherosclerosis risk reduction, based on the evaluation of specific features in individuals and tailoring management based on this evaluation. We plan to show that utilizing the iCARE Program, more patients will receive appropriate diagnoses and subsequent therapies in a more efficient manner.
Trial information was received from ClinicalTrials.gov and was last updated in May 2016.
Information provided to ClinicalTrials.gov by Piedmont Healthcare.